CLOs on the Move

Epic Sciences

www.epicsciences.com

 
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic`s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient`s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic`s goal ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Joel Smith
 General Counsel and Executive Vice President of Corporate Development Profile
Joel Smith
 Executive Vice President of Corporate Development, General Counsel and Chief Compliance Officer Profile

Similar Companies

Q Bio

Our Q Exam is based on landmark systems biology research done at Stanford University. In about 75 minutes, we take blood, saliva, urine and a non-invasive whole-body scan from which we measure over 3000 clinically-relevant genetic, chemical, and anatomical biomarkers to build the world`s most comprehensive quantitative snapshot of your health at a point in time.

Oceanit Laboratories

Oceanit Laboratories, Inc. is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Temporary Technical Services Inc

Temporary Technical Services Inc is a Jackson, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nortern Lipids

Nortern Lipids is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Immunicom

Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.